{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:57:12Z","timestamp":1776351432254,"version":"3.51.2"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Doxorubicin (DOX), a widely used anthracycline in cancer therapy, is associated with significant cardiovascular toxicity. While its cardiotoxic effects are well documented, the mechanisms and prevention of DOX-induced vascular toxicity remain insufficiently explored. Angiotensin-converting enzyme inhibitors (ACEIs), such as perindopril (PER), are commonly used in cardiovascular disease management and may offer vascular protection during chemotherapy. Female ovariectomized Wistar rats were treated with\n                    <jats:italic>i.v.<\/jats:italic>\n                    DOX and\/or\n                    <jats:italic>p.o.<\/jats:italic>\n                    PER over five weeks. Cardiac and vascular function were assessed using high-frequency ultrasound and ECG. Vascular reactivity was evaluated in isolated aortal rings using phenylephrine (PE), acetylcholine (ACh), L-N-Nitro arginine methyl ester hydrochloride (L-NAME), and verapamil (VER). Oxidative stress was assessed via plasma 4-hydroxy-2-nonenal (4-HNE) levels, and structural changes were monitored through intima-media thickness (IMT) measurements. DOX administration significantly impaired vascular reactivity, as evidenced by increased contractile responses to PE and reduced endothelium-dependent relaxation. These functional alterations were accompanied by elevated plasma 4-HNE levels, indicating enhanced oxidative stress. Co-treatment with PER preserved vascular responsiveness, reduced contractile tension, and significantly lowered 4-HNE concentrations. Structurally, IMT increased in control and PER-only groups, likely due to post-ovariectomy remodelling, while DOX-treated groups showed no IMT progression. PER co-treatment appeared to stabilize IMT values. PER mitigates DOX-induced vascular toxicity, likely through endothelial protection and reduction of oxidative stress. These findings support the potential use of ACEIs as prophylactic agents in patients undergoing anthracycline-based chemotherapy and highlight the need for further translational studies in cardio-oncology.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12012-026-10092-0","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:00:12Z","timestamp":1769522412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Perindopril in Mitigating Doxorubicin\u2019s Vascular Toxicity in a Rat Model"],"prefix":"10.1007","volume":"26","author":[{"given":"Anna","family":"Marada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Stra\u010dina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Marhefka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"\u0160\u016fstkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"N\u00e1den\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindra","family":"Smutn\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Scheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Hlo\u017ekov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Hendrych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Studenik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Paulov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Nov\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"10092_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.mayocpiqo.2021.05.005","volume":"5","author":"K ReFaey","year":"2021","unstructured":"ReFaey, K., Tripathi, S., Grewal, S. S., Bhargav, A. G., Quinones, D. J., Chaichana, K. L., Antwi, S. O., Cooper, L. T., Meyer, F. B., Dronca, R. S., Diasio, R. B., & Quinones-Hinojosa, A. (2021). Cancer mortality rates increasing vs cardiovascular disease mortality decreasing in the world: Future implications. Mayo Clin Proc Innov Qual Outcomes, 5, 645\u2013653.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10092_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ehjcvp\/pvae013","volume":"10","author":"J Tamargo","year":"2024","unstructured":"Tamargo, J., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinandy, P., Grove, E. L., Rocca, B., Magavern, E., Sulzgruber, P., Semb, A. G., Sossalla, S., Niessner, A., Kaski, J. C., & Dobrev, D. (2024). New Pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. Eur Heart J Cardiovasc Pharmacother, 10, 219\u2013244.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10092_CR3","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., & Denberg, T. D. (2011). Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Research, 13, R64.","journal-title":"Breast Cancer Research"},{"key":"10092_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","volume":"27","author":"PT Bradshaw","year":"2016","unstructured":"Bradshaw, P. T., Stevens, J., Khankari, N., Teitelbaum, S. L., Neugut, A. I., & Gammon, M. D. (2016). Cardiovascular disease mortality among breast cancer survivors. Epidemiology (Cambridge, Mass.), 27, 6\u201313.","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"10092_CR5","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","volume":"116","author":"CG Tocchetti","year":"2020","unstructured":"Tocchetti, C. G., Ameri, P., de Boer, R. A., D\u2019Alessandra, Y., Russo, M., Sorriento, D., Ciccarelli, M., Kiss, B., Bertrand, L., Dawson, D., Falcao-Pires, I., Giacca, M., Hamdani, N., Linke, W. A., Mayr, M., van der Velden, J., Zacchigna, S., Ghigo, A., Hirsch, E., \u2026 and, & Thum, T. (2020). Cardiac dysfunction in cancer patients: Beyond direct cardiomyocyte damage of anticancer drugs: Novel cardio-oncology insights from the joint 2019 meeting of the ESC working groups of myocardial function and cellular biology of the heart. Cardiovasc Res, 116, 1820\u20131834.","journal-title":"Cardiovasc Res"},{"key":"10092_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and Pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185\u2013229.","journal-title":"Pharmacological Reviews"},{"key":"10092_CR7","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy, 139, 111708.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10092_CR8","doi-asserted-by":"crossref","unstructured":"Holanek, M., Selingerova, I., Bilek, O., Kazda, T., Fabian, P., Foretova, L., Zvarikova, M., Obermannova, R., Kolouskova, I., Coufal, O., Petrakova, K., Svoboda, M., & Poprach, A. (2021). Neoadjuvant chemotherapy of Triple-Negative breast cancer: Evaluation of early clinical response, pathological complete response Rates, and addition of platinum salts benefit based on Real-World evidence. Cancers (Basel) 13.","DOI":"10.3390\/cancers13071586"},{"key":"10092_CR9","first-page":"405","volume":"28","author":"J Navr\u00e1til","year":"2015","unstructured":"Navr\u00e1til, J., Fabian, P., Pal\u00e1cov\u00e1, M., Petr\u00e1kov\u00e1, K., Vyzula, R., & Svoboda, M. (2015). [Triple negative breast Cancer]. Klinick\u00e1 Onkologie : Casopis Cesk\u00e9 A Slovensk\u00e9 Onkologick\u00e9 Spolecnosti, 28, 405\u2013415.","journal-title":"Klinick\u00e1 Onkologie : Casopis Cesk\u00e9 A Slovensk\u00e9 Onkologick\u00e9 Spolecnosti"},{"key":"10092_CR10","doi-asserted-by":"publisher","first-page":"1388869","DOI":"10.3389\/fonc.2024.1388869","volume":"14","author":"Y Qiu","year":"2024","unstructured":"Qiu, Y., Chen, Y., Shen, H., Yan, S., Li, J., & Wu, W. (2024). Triple-negative breast cancer survival prediction: population-based research using the SEER database and an external validation cohort. Frontiers in Oncology, 14, 1388869.","journal-title":"Frontiers in Oncology"},{"key":"10092_CR11","doi-asserted-by":"crossref","unstructured":"Garufi, G., Carbognin, L., Schettini, F., Segu\u00ed, E., Di Leone, A., Franco, A., Paris, I., Scambia, G., Tortora, G., & Fabi, A. (2022). Updated neoadjuvant treatment landscape for early triple negative breast cancer: Immunotherapy, potential predictive Biomarkers, and novel agents. Cancers (Basel) 14.","DOI":"10.3390\/cancers14174064"},{"key":"10092_CR12","doi-asserted-by":"crossref","unstructured":"Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics 15.","DOI":"10.20944\/preprints202306.0074.v1"},{"key":"10092_CR13","doi-asserted-by":"publisher","first-page":"e390464","DOI":"10.1200\/EDBK_390464","volume":"43","author":"HS Han","year":"2023","unstructured":"Han, H. S., Vikas, P., Costa, R. L. B., Jahan, N., Taye, A., & Stringer-Reasor, E. M. (2023). Early-Stage Triple-Negative breast cancer journey: Beginning, End, and everything in between. Am Soc Clin Oncol Educ Book, 43, e390464.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10092_CR14","doi-asserted-by":"crossref","unstructured":"Lee, J. (2023). Current treatment landscape for early Triple-Negative breast cancer (TNBC). J Clin Med 12.","DOI":"10.3390\/jcm12041524"},{"key":"10092_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00210-023-02382-z","volume":"396","author":"PL Dulf","year":"2023","unstructured":"Dulf, P. L., Mocan, M., Coad\u0103, C. A., Dulf, D. V., Moldovan, R., Baldea, I., Farcas, A. D., Blendea, D., & Filip, A. G. (2023). Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model. Naunyn-Schmiedeberg\u2019S Archives of Pharmacology, 396, 1105\u20131115.","journal-title":"Naunyn-Schmiedeberg\u2019S Archives of Pharmacology"},{"key":"10092_CR16","doi-asserted-by":"crossref","unstructured":"Vitale, R., Marzocco, S., & Popolo, A. (2024). Role of oxidative stress and inflammation in Doxorubicin-Induced cardiotoxicity: A brief account. International Journal of Molecular Sciences 25.","DOI":"10.20944\/preprints202405.1681.v1"},{"key":"10092_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/med.21280","volume":"34","author":"FS Carvalho","year":"2014","unstructured":"Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014). Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Medicinal Research Reviews, 34, 106\u2013135.","journal-title":"Medicinal Research Reviews"},{"key":"10092_CR18","first-page":"18","volume":"5","author":"N Bansal","year":"2019","unstructured":"Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology, 5, 18.","journal-title":"Cardiooncology"},{"key":"10092_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., & de Azambuja, E. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 31, 171\u2013190. \u2026 and clinicalguidelines@esmo.org, E.G.C.E.a.","journal-title":"Annals of Oncology"},{"key":"10092_CR20","first-page":"e59461","volume":"16","author":"J Singh","year":"2024","unstructured":"Singh, J., Iqbal, S. A., Gajula, S., Raghavan, P., Rajpal, S., & Khan, A. (2024). Assessment of Chemotherapy-Induced cardiac dysfunction in breast cancer patients: A prospective study. Cureus, 16, e59461.","journal-title":"Cureus"},{"key":"10092_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","volume":"27","author":"P Sobczuk","year":"2022","unstructured":"Sobczuk, P., Czerwi\u0144ska, M., Kleibert, M., & Cudnoch-J\u0119drzejewska, A. (2022). Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Failure Reviews, 27, 295\u2013319.","journal-title":"Heart Failure Reviews"},{"key":"10092_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","volume":"3","author":"AZ Luu","year":"2018","unstructured":"Luu, A. Z., Chowdhury, B., Al-Omran, M., Teoh, H., Hess, D. A., & Verma, S. (2018). Role of endothelium in Doxorubicin-Induced cardiomyopathy. JACC Basic Transl Sci, 3, 861\u2013870.","journal-title":"JACC Basic Transl Sci"},{"key":"10092_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cbi.2019.01.032","volume":"303","author":"N Koleini","year":"2019","unstructured":"Koleini, N., Nickel, B. E., Edel, A. L., Fandrich, R. R., Ravandi, A., & Kardami, E. (2019). Oxidized phospholipids in Doxorubicin-induced cardiotoxicity. Chem Biol Interact, 303, 35\u201339.","journal-title":"Chem Biol Interact"},{"key":"10092_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/1389200218666170105165444","volume":"18","author":"M Fojtu","year":"2017","unstructured":"Fojtu, M., Gumulec, J., Stracina, T., Raudenska, M., Skotakova, A., Vaculovicova, M., Adam, V., Babula, P., Novakova, M., & Masarik, M. (2017). Reduction of Doxorubicin-Induced cardiotoxicity using nanocarriers: A review. Current Drug Metabolism, 18, 237\u2013263.","journal-title":"Current Drug Metabolism"},{"key":"10092_CR25","doi-asserted-by":"crossref","unstructured":"Kala, P., Bartu\u0161kov\u00e1, H., Pi\u0165ha, J., Va\u0148ourkov\u00e1, Z., Kikerlov\u00e1, S., J\u00edchov\u00e1, \u0160., Melenovsk\u00fd, V., Ho\u0161kov\u00e1, L., Veselka, J., Kompanowska-Jezierska, E., Sadowski, J., Gawrys, O., Maxov\u00e1, H., & \u010cervenka, L. (2020). Deleterious effects of hyperactivity of the Renin-Angiotensin system and hypertension on the course of Chemotherapy-Induced heart failure after doxorubicin administration: A study in Ren-2 Transgenic rat. International Journal of Molecular Sciences 21.","DOI":"10.3390\/ijms21249337"},{"key":"10092_CR26","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati, G., Heck, S. L., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W., Gravdehaug, B., von Knobelsdorff-Brenkenhoff, F., Bratland, \u00c5., Stor\u00e5s, T. H., Hagve, T. A., R\u00f8sj\u00f8, H., Steine, K., Geisler, J., & Omland, T. (2016). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal, 37, 1671\u20131680.","journal-title":"European Heart Journal"},{"key":"10092_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai, G., Nabati, M., Faghihinia, M., Azizi, S., Borhani, S., & Yazdani, J. (2017). Effect of Enalapril on preventing Anthracycline-Induced cardiomyopathy. Cardiovascular Toxicology, 17, 130\u2013139.","journal-title":"Cardiovascular Toxicology"},{"key":"10092_CR28","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","volume":"104","author":"H Nakamae","year":"2005","unstructured":"Nakamae, H., Tsumura, K., Terada, Y., Nakane, T., Nakamae, M., Ohta, K., Yamane, T., & Hino, M. (2005). Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer, 104, 2492\u20132498.","journal-title":"Cancer"},{"key":"10092_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/COC.0000000000000389","volume":"41","author":"S Wittayanukorn","year":"2018","unstructured":"Wittayanukorn, S., Qian, J., Westrick, S. C., Billor, N., Johnson, B., & Hansen, R. A. (2018). Prevention of trastuzumab and Anthracycline-induced cardiotoxicity using Angiotensin-converting enzyme inhibitors or \u03b2-blockers in older adults with breast cancer. American Journal of Clinical Oncology, 41, 909\u2013918.","journal-title":"American Journal of Clinical Oncology"},{"key":"10092_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12935-023-03080-9","volume":"23","author":"B Hassani","year":"2023","unstructured":"Hassani, B., Attar, Z., & Firouzabadi, N. (2023). The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: Foes versus allies. Cancer Cell International, 23, 254.","journal-title":"Cancer Cell International"},{"key":"10092_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George, A. J., Thomas, W. G., & Hannan, R. D. (2010). The renin-angiotensin system and cancer: Old dog, new tricks. Nature Reviews Cancer, 10, 745\u2013759.","journal-title":"Nature Reviews Cancer"},{"key":"10092_CR32","doi-asserted-by":"crossref","unstructured":"Al-Biltagi, M., Tolba, A. R. E., & El-Shanshory, O. (2012). M.R., Abd El-Aziz El-Shitany, N. and El-Sayed El-Hawary, E. Strain echocardiography in early detection of Doxorubicin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. ISRN Pediatr 2012: 870549.","DOI":"10.5402\/2012\/870549"},{"key":"10092_CR33","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1006\/jmcc.1999.0972","volume":"31","author":"RJ Boucek","year":"1999","unstructured":"Boucek, R. J., Miracle, A., Anderson, M., Engelman, R., Atkinson, J., & Dodd, D. A. (1999). Persistent effects of doxorubicin on cardiac gene expression. Journal of Molecular and Cellular Cardiology, 31, 1435\u20131446.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10092_CR34","first-page":"101332","volume":"50","author":"C Belger","year":"2024","unstructured":"Belger, C., Abrahams, C., Imamdin, A., & Lecour, S. (2024). Doxorubicin-induced cardiotoxicity and risk factors. Int J Cardiol Heart Vasc, 50, 101332.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10092_CR35","doi-asserted-by":"crossref","unstructured":"Chaulin, A. M. (2023). The essential strategies to mitigate cardiotoxicity caused by doxorubicin. Life (Basel) 13.","DOI":"10.3390\/life13112148"},{"key":"10092_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jaccao.2020.06.010","volume":"2","author":"ZS Clayton","year":"2020","unstructured":"Clayton, Z. S., Brunt, V. E., Hutton, D. A., VanDongen, N. S., D\u2019Alessandro, A., Reisz, J. A., Ziemba, B. P., & Seals, D. R. (2020). Doxorubicin-Induced oxidative stress and endothelial dysfunction in conduit arteries is prevented by Mitochondrial-Specific antioxidant treatment. JACC CardioOncol, 2, 475\u2013488.","journal-title":"JACC CardioOncol"},{"key":"10092_CR37","doi-asserted-by":"crossref","unstructured":"Bosman, M., Kr\u00fcger, D. N., Favere, K., Wesley, C. D., Neutel, C. H. G., Van Asbroeck, B., Diebels, O. R., Faes, B., Schenk, T. J., Martinet, W., De Meyer, G. R. Y., Van Craenenbroeck, E. M., & Guns, P. D. F. (2021). Doxorubicin impairs smooth muscle cell contraction: Novel insights in vascular toxicity. International Journal of Molecular Sciences 22.","DOI":"10.3390\/ijms222312812"},{"key":"10092_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.phrs.2013.08.003","volume":"76","author":"M Monti","year":"2013","unstructured":"Monti, M., Terzuoli, E., Ziche, M., & Morbidelli, L. (2013). The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis. Pharmacological Research, 76, 171\u2013181.","journal-title":"Pharmacological Research"},{"key":"10092_CR39","doi-asserted-by":"crossref","unstructured":"Szczepaniak, P., Siedlinski, M., Hodorowicz-Zaniewska, D., Nosalski, R., Mikolajczyk,T.P., Dobosz, A.M., Dikalova, A., Dikalov, S., Streb, J., Gara, K., Basta, P., Krolczyk,J., Sulicka-Grodzicka, J., Jozefczuk, E., Dziewulska, A., Saju, B., Laksa, I., Chen,W., Dormer, J., \u2026 and Guzik, T.J. (2022). Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. J Clin Invest 132.","DOI":"10.1172\/JCI149117"},{"key":"10092_CR40","doi-asserted-by":"publisher","first-page":"114576","DOI":"10.1016\/j.biopha.2023.114576","volume":"162","author":"E Podyacheva","year":"2023","unstructured":"Podyacheva, E., Danilchuk, M., & Toropova, Y. (2023). Molecular mechanisms of endothelial remodeling under doxorubicin treatment. Biomedicine & Pharmacotherapy, 162, 114576.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10092_CR41","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/aps.2009.145","volume":"30","author":"B Shen","year":"2009","unstructured":"Shen, B., Ye, C. L., Ye, K. H., Zhuang, L., & Jiang, J. H. (2009). Doxorubicin-induced vasomotion and [Ca(2+)](i) elevation in vascular smooth muscle cells from C57BL\/6 mice. Acta Pharmacologica Sinica, 30, 1488\u20131495.","journal-title":"Acta Pharmacologica Sinica"},{"key":"10092_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxlet.2021.04.015","volume":"346","author":"M Bosman","year":"2021","unstructured":"Bosman, M., Favere, K., Neutel, C. H. G., Jacobs, G., De Meyer, G. R. Y., Martinet, W., Van Craenenbroeck, E. M., & Guns, P. D. F. (2021). Doxorubicin induces arterial stiffness: A comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice. Toxicology Letters, 346, 23\u201333.","journal-title":"Toxicology Letters"},{"key":"10092_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/FJC.0b013e31829c9993","volume":"62","author":"NM Gibson","year":"2013","unstructured":"Gibson, N. M., Greufe, S. E., Hydock, D. S., & Hayward, R. (2013). Doxorubicin-induced vascular dysfunction and its Attenuation by exercise preconditioning. Journal of Cardiovascular Pharmacology, 62, 355\u2013360.","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10092_CR44","first-page":"260","volume":"9","author":"M Olukman","year":"2009","unstructured":"Olukman, M., Can, C., Erol, A., Oktem, G., Oral, O., & Cinar, M. G. (2009). Reversal of doxorubicin-induced vascular dysfunction by Resveratrol in rat thoracic aorta: Is there a possible role of nitric oxide synthase inhibition? Anadolu Kardiyoloji Dergisi : Akd = The Anatolian Journal of Cardiology, 9, 260\u2013266.","journal-title":"Anadolu Kardiyoloji Dergisi : Akd = The Anatolian Journal of Cardiology"},{"key":"10092_CR45","doi-asserted-by":"crossref","unstructured":"Bart\u00e1kov\u00e1, A., Kolou\u0161kov\u00e1, I., Hol\u00e1nek, M., Selingerov\u00e1, I., Stra\u010dina, T., Kazda, T., & Nov\u00e1kov\u00e1, M. (2023). Cardiovascular Pharmacotherapy in Patients with Triple Negative Breast Cancer Before and After Anthracycline Treatment., Klinick\u00e1 onkologie.","DOI":"10.48095\/ccko2023S123"},{"key":"10092_CR46","doi-asserted-by":"crossref","unstructured":"Netala, V. R., Teertam, S. K., Li, H., & Zhang, Z. (2024). A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells 13.","DOI":"10.3390\/cells13171471"},{"key":"10092_CR47","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1248\/cpb.34.1694","volume":"34","author":"K Yoshino","year":"1986","unstructured":"Yoshino, K., Matsuura, T., Sano, M., Saito, S., & Tomita, I. (1986). Fluorometric liquid chromatographic determination of aliphatic aldehydes arising from lipid peroxides. Chem Pharm Bull (Tokyo), 34, 1694\u20131700.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10092_CR48","doi-asserted-by":"crossref","unstructured":"de Boer, R.A., De Keulenaer, G., Bauersachs, J., Brutsaert, D., Cleland, J.G., Diez,J., Du, X.J., Ford, P., Heinzel, F.R., Lipson, K.E., McDonagh, T., Lopez-Andres, N.,Lunde, I.G., Lyon, A.R., Pollesello, P., Prasad, S.K., Tocchetti, C.G., Mayr, M.,Sluijter, J.P.G., \u2026 and Heymans, S. (2019). Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail 21: 272\u2013285.","DOI":"10.1002\/ejhf.1406"},{"key":"10092_CR49","doi-asserted-by":"publisher","first-page":"e15120","DOI":"10.14814\/phy2.15120","volume":"9","author":"L Jin","year":"2021","unstructured":"Jin, L., & Conklin, D. J. (2021). A novel evaluation of endothelial dysfunction ex vivo: Teaching an old drug a new trick. Physiol Rep, 9, e15120.","journal-title":"Physiol Rep"},{"key":"10092_CR50","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer, 97, 2869\u20132879.","journal-title":"Cancer"},{"key":"10092_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1081\/CNV-100000150","volume":"19","author":"EA Perez","year":"2001","unstructured":"Perez, E. A. (2001). Doxorubicin and Paclitaxel in the treatment of advanced breast cancer: Efficacy and cardiac considerations. Cancer Investigation, 19, 155\u2013164.","journal-title":"Cancer Investigation"},{"key":"10092_CR52","doi-asserted-by":"publisher","first-page":"e008209","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","volume":"14","author":"E Jirkovsk\u00fd","year":"2021","unstructured":"Jirkovsk\u00fd, E., Jirkovsk\u00e1, A., Bavlovi\u010d-Pisk\u00e1\u010dkov\u00e1, H., Skalick\u00e1, V., Pokorn\u00e1, Z., Karabanovich, G., Koll\u00e1rov\u00e1-Br\u00e1zdov\u00e1, P., Kube\u0161, J., Len\u010dov\u00e1-Popelov\u00e1, O., Mazurov\u00e1, Y., Adamcov\u00e1, M., Lyon, A. R., Roh, J., \u0160im\u016fnek, T., \u0160t\u011brbov\u00e1-Kova\u0159\u00edkov\u00e1, P., & \u0160t\u011brba, M. (2021). Clinically translatable prevention of anthracycline cardiotoxicity by Dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circulation. Heart Failure, 14, e008209.","journal-title":"Circulation. Heart Failure"},{"key":"10092_CR53","first-page":"670","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss, R. B. (1992). The anthracyclines: Will we ever find a better doxorubicin? Seminars in Oncology, 19, 670\u2013686.","journal-title":"Seminars in Oncology"},{"key":"10092_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2019.04.014","volume":"124","author":"Y Wei","year":"2019","unstructured":"Wei, Y., Elahy, M., Friedhuber, A. M., Wong, J. Y., Hughes, J. D., Doschak, M. R., & Dass, C. R. (2019). Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin. Bone, 124, 103\u2013117.","journal-title":"Bone"},{"key":"10092_CR55","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1161\/CIRCULATIONAHA.105.560250","volume":"113","author":"K Li","year":"2006","unstructured":"Li, K., Sung, R. Y., Huang, W. Z., Yang, M., Pong, N. H., Lee, S. M., Chan, W. Y., Zhao, H., To, M. Y., Fok, T. F., Li, C. K., Wong, Y. O., & Ng, P. C. (2006). Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation, 113, 2211\u20132220.","journal-title":"Circulation"},{"key":"10092_CR56","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.biopha.2017.04.033","volume":"90","author":"AI Abushouk","year":"2017","unstructured":"Abushouk, A. I., Ismail, A., Salem, A. M. A., Afifi, A. M., & Abdel-Daim, M. M. (2017). Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomedicine & Pharmacotherapy, 90, 935\u2013946.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10092_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12012-007-0018-0","volume":"7","author":"A Bast","year":"2007","unstructured":"Bast, A., Haenen, G. R., Bruynzeel, A. M., & Van der Vijgh, W. J. (2007). Protection by flavonoids against anthracycline cardiotoxicity: From chemistry to clinical trials. Cardiovascular Toxicology, 7, 154\u2013159.","journal-title":"Cardiovascular Toxicology"},{"key":"10092_CR58","doi-asserted-by":"publisher","first-page":"608136","DOI":"10.3389\/fphar.2020.608136","volume":"11","author":"L Cong","year":"2020","unstructured":"Cong, L., Ren, Y., Hou, T., Han, X., Dong, Y., Wang, Y., Zhang, Q., Liu, R., Xu, S., Wang, L., Du, Y., & Qiu, C. (2020). Use of cardiovascular drugs for primary and secondary prevention of cardiovascular disease among Rural-Dwelling older Chinese adults. Frontiers in Pharmacology, 11, 608136.","journal-title":"Frontiers in Pharmacology"},{"key":"10092_CR59","doi-asserted-by":"publisher","first-page":"e0294848","DOI":"10.1371\/journal.pone.0294848","volume":"18","author":"M Bosman","year":"2023","unstructured":"Bosman, M., Kr\u00fcger, D. N., Favere, K., De Meyer, G. R. Y., Franssen, C., Van Craenenbroeck, E. M., & Guns, P. J. (2023). Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice. PLoS One, 18, e0294848.","journal-title":"PLoS One"},{"key":"10092_CR60","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/toxsci\/kfae008","volume":"198","author":"V Kereste\u0161","year":"2024","unstructured":"Kereste\u0161, V., Kube\u0161, J., Applov\u00e1, L., Koll\u00e1rov\u00e1, P., Len\u010dov\u00e1-Popelov\u00e1, O., Melnikova, I., Karabanovich, G., Khazeem, M. M., Bavlovi\u010d-Pisk\u00e1\u010dkov\u00e1, H., \u0160t\u011brbov\u00e1-Kova\u0159\u00edkov\u00e1, P., Austin, C. A., Roh, J., \u0160t\u011brba, M., \u0160im\u016fnek, T., & Jirkovsk\u00e1, A. (2024). Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Toxicological Sciences, 198, 288\u2013302.","journal-title":"Toxicological Sciences"},{"key":"10092_CR61","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/jpp\/rgac063","volume":"74","author":"IC Jones","year":"2022","unstructured":"Jones, I. C., & Dass, C. R. (2022). Doxorubicin-induced cardiotoxicity: Causative factors and possible interventions. Journal of Pharmacy and Pharmacology, 74, 1677\u20131688.","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10092_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-020-05703-5","volume":"182","author":"H Cho","year":"2020","unstructured":"Cho, H., Lee, S., Sim, S. H., Park, I. H., Lee, K. S., Kwak, M. H., & Kim, H. J. (2020). Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Research and Treatment, 182, 333\u2013343.","journal-title":"Breast Cancer Research and Treatment"},{"key":"10092_CR63","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1472-8206.2010.00854.x","volume":"24","author":"K Komukai","year":"2010","unstructured":"Komukai, K., Mochizuki, S., & Yoshimura, M. (2010). Gender and the renin-angiotensin-aldosterone system. Fundamental & Clinical Pharmacology, 24, 687\u2013698.","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10092_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","volume":"37","author":"A Al Shoyaib","year":"2019","unstructured":"Al Shoyaib, A., Archie, S. R., & Karamyan, V. T. (2019). Intraperitoneal route of drug administration: Should it be used in experimental animal. Studies? Pharm Res, 37, 12.","journal-title":"Studies? Pharm Res"},{"key":"10092_CR65","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2165\/00003495-200161060-00020","volume":"61","author":"M Hurst","year":"2001","unstructured":"Hurst, M., & Jarvis, B. (2001). Perindopril: An updated review of its use in hypertension. Drugs, 61, 867\u2013896.","journal-title":"Drugs"},{"key":"10092_CR66","doi-asserted-by":"crossref","unstructured":"Denny, K. H., & Stewart, C. W. (2024). Acute, Subacute, Subchronic, and Chronic General Toxicity Testing for Preclinical Drug Development. In: Faqi, A. S., editor. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. 3rd ed. Academic Press 149\u2013171.","DOI":"10.1016\/B978-0-323-85704-8.00016-5"},{"key":"10092_CR67","doi-asserted-by":"publisher","first-page":"1176748","DOI":"10.3389\/fphys.2023.1176748","volume":"14","author":"R Schubert","year":"2023","unstructured":"Schubert, R., Gaynullina, D., Shvetsova, A., & Tarasova, O. S. (2023). Myography of isolated blood vessels: Considerations for experimental design and combination with supplementary techniques. Frontiers in Physiology, 14, 1176748.","journal-title":"Frontiers in Physiology"},{"key":"10092_CR68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.lfs.2015.12.043","volume":"145","author":"M Rameshrad","year":"2016","unstructured":"Rameshrad, M., Babaei, H., Azarmi, Y., & Fouladi, D. F. (2016). Rat aorta as a Pharmacological tool for in vitro and in vivo studies. Life Sciences, 145, 190\u2013204.","journal-title":"Life Sciences"},{"key":"10092_CR69","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/00007890-199205000-00007","volume":"53","author":"JY Jeremy","year":"1992","unstructured":"Jeremy, J. Y., Stansby, G., Fuller, B., Rolles, K., & Hamilton, G. (1992). The effect of cold storage of rat thoracic aortic rings in organ preservation solutions\u2013a study of receptor-linked vascular Prostacyclin synthesis. Transplantation, 53, 999\u20131002.","journal-title":"Transplantation"},{"key":"10092_CR70","unstructured":"Demirel, S. (2022). Effect of Cold Storage in Krebs-Henseleit Solution at +\u20094\u00b0C on Vasoreactivity of the Rat Thoracic Aorta, pp456\u2013461, Bal\u0131kesir Sa\u011fl\u0131k Bilimleri Dergisi."},{"key":"10092_CR71","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/000331976101201009","volume":"12","author":"DF Bohr","year":"1961","unstructured":"Bohr, D. F., Goulet, P. L., & Taquini, A. C. (1961). Direct tension recording from smooth muscle of resistance vessels from various organs. Angiology, 12, 478\u2013485.","journal-title":"Angiology"},{"key":"10092_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejphar.2012.09.016","volume":"696","author":"J van Langen","year":"2012","unstructured":"van Langen, J., Fransen, P., Van Hove, C. E., Schrijvers, D. M., Martinet, W., De Meyer, G. R., & Bult, H. (2012). Selective loss of basal but not receptor-stimulated relaxation by endothelial nitric oxide synthase after isolation of the mouse aorta. European Journal of Pharmacology, 696, 111\u2013119.","journal-title":"European Journal of Pharmacology"},{"key":"10092_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0022-3565(25)05163-8","volume":"108","author":"RF Furchgott","year":"1953","unstructured":"Furchgott, R. F., & Bhadrakom, S. (1953). Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. Journal of Pharmacology and Experimental Therapeutics, 108, 129\u2013143.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10092_CR74","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1111\/j.1582-4934.2009.00891.x","volume":"13","author":"RF Nicosia","year":"2009","unstructured":"Nicosia, R. F. (2009). The aortic ring model of angiogenesis: A quarter century of search and discovery. Journal of Cellular and Molecular Medicine, 13, 4113\u20134136.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10092_CR75","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bjp.0702855","volume":"128","author":"J Jiang","year":"1999","unstructured":"Jiang, J., Thor\u00e9n, P., Caligiuri, G., Hansson, G. K., & Pernow, J. (1999). Enhanced phenylephrine-induced rhythmic activity in the atherosclerotic mouse aorta via an increase in opening of KCa channels: Relation to Kv channels and nitric oxide. British Journal of Pharmacology, 128, 637\u2013646.","journal-title":"British Journal of Pharmacology"},{"key":"10092_CR76","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3389\/fphys.2017.00858","volume":"8","author":"A Leloup","year":"2017","unstructured":"Leloup, A., De Moudt, S., Van Hove, C., & Fransen, P. (2017). Cyclic stretch alters vascular reactivity of mouse aortic segments. Frontiers in Physiology, 8, 858.","journal-title":"Frontiers in Physiology"},{"key":"10092_CR77","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.lfs.2010.03.020","volume":"86","author":"GJ Chang","year":"2010","unstructured":"Chang, G. J., Lin, T. P., Ko, Y. S., & Lin, M. S. (2010). Endothelium-dependent and -independent vasorelaxation induced by CIJ-3-2F, a novel benzyl-furoquinoline with antiarrhythmic action, in rat aorta. Life Sciences, 86, 869\u2013879.","journal-title":"Life Sciences"},{"key":"10092_CR78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1537-1891(02)00311-7","volume":"40","author":"CE Damiani","year":"2003","unstructured":"Damiani, C. E., Rossoni, L. V., & Vassallo, D. V. (2003). Vasorelaxant effects of Eugenol on rat thoracic aorta. Vascular Pharmacology, 40, 59\u201366.","journal-title":"Vascular Pharmacology"},{"key":"10092_CR79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejphar.2011.01.043","volume":"656","author":"H Toba","year":"2011","unstructured":"Toba, H., Morishita, M., Tojo, C., Nakano, A., Oshima, Y., Kojima, Y., Yoshida, M., Nakashima, K., Wang, J., Kobara, M., & Nakata, T. (2011). Recombinant human erythropoietin ameliorated endothelial dysfunction and macrophage infiltration by increasing nitric oxide in hypertensive 5\/6 nephrectomized rat aorta. European Journal of Pharmacology, 656, 81\u201387.","journal-title":"European Journal of Pharmacology"},{"key":"10092_CR80","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.fitote.2011.08.013","volume":"82","author":"M Inchoo","year":"2011","unstructured":"Inchoo, M., Chirdchupunseree, H., Pramyothin, P., & Jianmongkol, S. (2011). Endothelium-independent effects of phyllanthin and hypophyllanthin on vascular tension. Fitoterapia, 82, 1231\u20131236.","journal-title":"Fitoterapia"},{"key":"10092_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fphys.2019.00055","volume":"10","author":"A Guti\u00e9rrez","year":"2019","unstructured":"Guti\u00e9rrez, A., Contreras, C., S\u00e1nchez, A., & Prieto, D. (2019). Role of phosphatidylinositol 3-Kinase (PI3K), Mitogen-Activated protein kinase (MAPK), and protein kinase C (PKC) in calcium signaling pathways linked to the \u03b1. Frontiers in Physiology, 10, 55.","journal-title":"Frontiers in Physiology"},{"key":"10092_CR82","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1152\/advances.2000.24.1.13","volume":"24","author":"RJ Gonzales","year":"2000","unstructured":"Gonzales, R. J., Carter, R. W., & Kanagy, N. L. (2000). Laboratory demonstration of vascular smooth muscle function using rat aortic ring segments. Advances in Physiology Education, 24, 13\u201321.","journal-title":"Advances in Physiology Education"},{"key":"10092_CR83","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.freeradbiomed.2017.02.003","volume":"111","author":"BC Sousa","year":"2017","unstructured":"Sousa, B. C., Pitt, A. R., & Spickett, C. M. (2017). Chemistry and analysis of HNE and other prominent carbonyl-containing lipid oxidation compounds. Free Radical Biology and Medicine, 111, 294\u2013308.","journal-title":"Free Radical Biology and Medicine"},{"key":"10092_CR84","doi-asserted-by":"publisher","first-page":"670479","DOI":"10.3389\/fphar.2021.670479","volume":"12","author":"EY Podyacheva","year":"2021","unstructured":"Podyacheva, E. Y., Kushnareva, E. A., Karpov, A. A., & Toropova, Y. G. (2021). Analysis of models of Doxorubicin-Induced cardiomyopathy in rats and Mice. A modern view from the perspective of the pathophysiologist and the clinician. Frontiers in Pharmacology, 12, 670479.","journal-title":"Frontiers in Pharmacology"},{"key":"10092_CR85","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3390\/biom5042247","volume":"5","author":"RJ Schaur","year":"2015","unstructured":"Schaur, R. J., Siems, W., Bresgen, N., & Eckl, P. M. (2015). 4-Hydroxy-nonenal-A bioactive lipid peroxidation product. Biomolecules, 5, 2247\u20132337.","journal-title":"Biomolecules"},{"key":"10092_CR86","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","volume":"11","author":"H Esterbauer","year":"1991","unstructured":"Esterbauer, H., Schaur, R. J., & Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine, 11, 81\u2013128.","journal-title":"Free Radical Biology and Medicine"},{"key":"10092_CR87","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.abb.2016.11.003","volume":"617","author":"H Zhang","year":"2017","unstructured":"Zhang, H., & Forman, H. J. (2017). Signaling by 4-hydroxy-2-nonenal: Exposure protocols, target selectivity and degradation. Archives of Biochemistry and Biophysics, 617, 145\u2013154.","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"Suppl 5","key":"10092_CR88","doi-asserted-by":"publisher","first-page":"S653","DOI":"10.33549\/physiolres.933223","volume":"64","author":"M Hlav\u00e1\u010dov\u00e1","year":"2015","unstructured":"Hlav\u00e1\u010dov\u00e1, M., Gumulec, J., Stra\u010dina, T., Fojt\u016f, M., Raudensk\u00e1, M., Masa\u0159\u00edk, M., Nov\u00e1kov\u00e1, M., & Paulov\u00e1, H. (2015). Different doxorubicin formulations affect plasma 4-hydroxy-2-nonenal and gene expression of aldehyde dehydrogenase 3A1 and thioredoxin reductase 2 in rat. Physiological Research, 64(Suppl 5), S653\u2013660.","journal-title":"Physiological Research"},{"key":"10092_CR89","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/cdd.2013.138","volume":"20","author":"S Dalleau","year":"2013","unstructured":"Dalleau, S., Baradat, M., Gu\u00e9raud, F., & Huc, L. (2013). Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death and Differentiation, 20, 1615\u20131630.","journal-title":"Cell Death and Differentiation"},{"key":"10092_CR90","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40256-023-00573-w","volume":"23","author":"J Feng","year":"2023","unstructured":"Feng, J., & Wu, Y. (2023). Endothelial-to-Mesenchymal transition: Potential target of Doxorubicin-Induced cardiotoxicity. Am J Cardiovasc Drugs, 23, 231\u2013246.","journal-title":"Am J Cardiovasc Drugs"},{"key":"10092_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yjmcc.2015.12.010","volume":"90","author":"Z Sun","year":"2016","unstructured":"Sun, Z., Schriewer, J., Tang, M., Marlin, J., Taylor, F., Shohet, R. V., & Konorev, E. A. (2016). The TGF-\u03b2 pathway mediates doxorubicin effects on cardiac endothelial cells. Journal of Molecular and Cellular Cardiology, 90, 129\u2013138.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10092_CR92","doi-asserted-by":"crossref","unstructured":"Xu, A., Deng, F., Chen, Y., Kong, Y., Pan, L., Liao, Q., Rao, Z., Xie, L., Yao, C.,Li, S., Zeng, X., Zhu, X., Liu, H., Gao, N., Xue, L., Chen, F., Xu, G., Wei, D., Zhou,X., \u2026 and Sheng, X. (2020). NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomed Pharmacother 130: 110525.","DOI":"10.1016\/j.biopha.2020.110525"},{"key":"10092_CR93","doi-asserted-by":"crossref","unstructured":"Bart\u00e1kov\u00e1, A., & Nov\u00e1kov\u00e1, M. (2021). Secondary metabolites of plants as modulators of endothelium functions. International Journal of Molecular Sciences 22.","DOI":"10.3390\/ijms22052533"},{"key":"10092_CR94","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","volume":"8","author":"A Ancion","year":"2019","unstructured":"Ancion, A., Tridetti, J., Nguyen Trung, M. L., Oury, C., & Lancellotti, P. (2019). A review of the role of Bradykinin and nitric oxide in the cardioprotective action of Angiotensin-Converting enzyme inhibitors: Focus on Perindopril. Cardiol Ther, 8, 179\u2013191.","journal-title":"Cardiol Ther"},{"key":"10092_CR95","doi-asserted-by":"crossref","unstructured":"Be\u021biu, A. M., Noveanu, L., H\u00e2ncu, I. M., Lascu, A., Petrescu, L., Maack, C., Elm\u00e9r, E., & Muntean, D. M. (2022). Mitochondrial effects of common cardiovascular medications: The Good, the bad and the mixed. International Journal of Molecular Sciences 23.","DOI":"10.3390\/ijms232113653"},{"key":"10092_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2017.05.005","volume":"100","author":"MA Incalza","year":"2018","unstructured":"Incalza, M. A., D\u2019Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018). Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular Pharmacology, 100, 1\u201319.","journal-title":"Vascular Pharmacology"},{"key":"10092_CR97","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s11033-024-09803-z","volume":"51","author":"H Dhulkifle","year":"2024","unstructured":"Dhulkifle, H., Therachiyil, L., Hasan, M. H., Sayed, T. S., Younis, S. M., Korashy, H. M., Yalcin, H. C., & Maayah, Z. H. (2024). Inhibition of cytochrome P450 epoxygenase promotes endothelium-to-mesenchymal transition and exacerbates doxorubicin-induced cardiovascular toxicity. Molecular Biology Reports, 51, 859.","journal-title":"Molecular Biology Reports"},{"key":"10092_CR98","doi-asserted-by":"crossref","unstructured":"Chen, W., Kim, S., Kim, S., Beheshtian, C., Kim, N., Shin, K., Kim, R., Kim, S., & Park, N. (2025). GV1001, hTERT Peptide Fragment, Prevents Doxorubicin-Induced Endothelial-to-Mesenchymal Transition in Human Endothelial Cells and Atherosclerosis in Mice. CELLS 14.","DOI":"10.3390\/cells14020098"},{"key":"10092_CR99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10522-004-7383-x","volume":"6","author":"C Castillo","year":"2005","unstructured":"Castillo, C., Cruzado, M., Ariznavarreta, M., Lahera, V., Cachofeiro, V., Gil-Loyzaga, P., & Tresguerres, J. (2005). Effects of ovariectomy and growth hormone administration on body composition and vascular function and structure in old female rats. BIOGERONTOLOGY, 6, 49\u201360.","journal-title":"BIOGERONTOLOGY"},{"key":"10092_CR100","doi-asserted-by":"crossref","unstructured":"Schneider, A. P. H., Gaedke, M., Garcez, A., Barcellos, N. T., & Paniz, V. M. V. (2018). Effect of characteristics of pharmacotherapy on non-adherence in chronic cardiovascular disease: A systematic review and meta-analysis of observational studies. International Journal of Clinical Practice 72.","DOI":"10.1111\/ijcp.13044"},{"key":"10092_CR101","doi-asserted-by":"publisher","first-page":"e14987","DOI":"10.14814\/phy2.14987","volume":"9","author":"A Warhol","year":"2021","unstructured":"Warhol, A., George, S. A., Obaid, S. N., Efimova, T., & Efimov, I. R. (2021). Differential cardiotoxic electrocardiographic response to doxorubicin treatment in conscious versus anesthetized mice. Physiol Rep, 9, e14987.","journal-title":"Physiol Rep"},{"key":"10092_CR102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1476-5381.1991.tb12136.x","volume":"102","author":"M Urabe","year":"1991","unstructured":"Urabe, M., Kawasaki, H., & Takasaki, K. (1991). Effect of endothelium removal on the vasoconstrictor response to neuronally released 5-hydroxytryptamine and noradrenaline in the rat isolated mesenteric and femoral arteries. British Journal of Pharmacology, 102, 85\u201390.","journal-title":"British Journal of Pharmacology"},{"key":"10092_CR103","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1476-5381.1996.tb15447.x","volume":"118","author":"VA Randall","year":"1996","unstructured":"Randall, V. A., MacLennan, S. J., Martin, G. R., & Wilson, V. G. (1996). The effect of forskolin on 5-HT1-like and angiotensin II-induced vasoconstriction and Cyclic AMP content of the rabbit isolated femoral artery. British Journal of Pharmacology, 118, 627\u2013634.","journal-title":"British Journal of Pharmacology"},{"key":"10092_CR104","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0022-3565(25)38118-8","volume":"265","author":"RE Tessel","year":"1993","unstructured":"Tessel, R. E., Miller, D. W., Misse, G. A., Dong, X., & Doughty, M. B. (1993). Characterization of vascular postsynaptic neuropeptide Y receptor function and regulation. 1. NPY-induced constriction in isolated rat femoral artery rings is mediated by both Y1 and Y2 receptors: Evidence from Benextramine protection studies. Journal of Pharmacology and Experimental Therapeutics, 265, 172\u2013177.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10092_CR105","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1093\/oncolo\/oyae031","volume":"29","author":"Z Bielcikova","year":"2024","unstructured":"Bielcikova, Z., Holanek, M., Selingerova, I., Sorejs, O., Kolarova, I., Soumarova, R., Proks, J., Reifova, L., Cmejlova, V., Linkova, L., Zabojnikova, M., Chodacka, M., Janovska, L., Lisnerova, L., Kasparova, K., Pohankova, D., & Petruzelka, L. (2024). Treatment and prognosis of male breast cancer: A Multicentric, retrospective study over 11 years in the Czech Republic. The Oncologist, 29, e750\u2013e762.","journal-title":"The Oncologist"},{"key":"10092_CR106","doi-asserted-by":"publisher","first-page":"147032031990003","DOI":"10.1177\/1470320319900038","volume":"21","author":"J Flores-Monroy","year":"2020","unstructured":"Flores-Monroy, J., Lezama-Mart\u00ednez, D., Fonseca-Coronado, S., & Mart\u00ednez-Aguilar, L. (2020). Differences in the expression of the Renin angiotensin system and the kallikrein-kinin system during the course of myocardial infarction in male and female Wistar rats. J Renin Angiotensin Aldosterone Syst, 21, 1470320319900038.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10092_CR107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/CEJ.0000000000000784","volume":"32","author":"G Corso","year":"2023","unstructured":"Corso, G., Gandini, S., D\u2019Ecclesiis, O., Mazza, M., Magnoni, F., Veronesi, P., Galimberti, V., & La Vecchia, C. (2023). Risk and incidence of breast cancer in transgender individuals: A systematic review and meta-analysis. European Journal of Cancer Prevention, 32, 207\u2013214.","journal-title":"European Journal of Cancer Prevention"},{"key":"10092_CR108","first-page":"S727","volume":"73","author":"M Laska","year":"2024","unstructured":"Laska, M., Vitous, J., Jirik, R., Hendrych, M., Drazanova, E., Kratka, L., Nadenicek, J., Novakova, M., & Stracina, T. (2024). Heart remodelling affects ECG in rat DOCA\/Salt model. Phys Res, 73, S727\u2013S735.","journal-title":"Phys Res"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10092-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10092-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10092-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:17Z","timestamp":1771948997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10092-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10092"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10092-0","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All animal experiments were carried out according to the recommendations of the European Community Guide for the Care and Use of Laboratory Animals. The experimental protocol (No. MSMT-5763\/2024-3) was approved by the Committee for Ensuring the Welfare of Laboratory Animals of Masaryk University and licensed by the Ministry of Education, Youth and Sports of the Czech Republic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"19"}}